Omniome Revenue and Competitors

Location

$126.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Omniome's estimated annual revenue is currently $852.5k per year.(i)
  • Omniome received $60.0M in venture funding in July 2018.
  • Omniome's estimated revenue per employee is $77,500
  • Omniome's total funding is $126.6M.

Employee Data

  • Omniome has 11 Employees.(i)
  • Omniome grew their employee count by -39% last year.

Omniome's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
COOReveal Email/Phone
3
Chief Product OfficerReveal Email/Phone
4
Chief Operating OfficerReveal Email/Phone
5
Senior Manager, Software EngineeringReveal Email/Phone
6
Scientist II, ManagerReveal Email/Phone
7
Scientist I - EnzymologyReveal Email/Phone
8
Associte ScientistReveal Email/Phone
9
Senior Mechanical EngineerReveal Email/Phone
10
Engineer 3 - System IntegrationReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4280M11139-4%$28M$63.3B
Add Company

What Is Omniome?

Based in San Diego and founded in 2013, Omniome is a biotechnology company developing a breakthrough DNA sequencing platform that delivers highly accurate and fast results at low cost with the potential to advance cancer diagnostics, drive high fidelity single-cell applications and broadly support clinical sequencing. Our scar-free, Sequencing By Binding (SBB) technology provides enhanced precision of nucleotide and DNA matching by leveraging the natural matching ability of the polymerase, decreasing runtimes and increasing the number of samples per run. We offer a stimulating, fast-paced, start-up work environment where innovative and highly-motivated team players will thrive.

keywords:N/A

$126.6M

Total Funding

11

Number of Employees

$852.5k

Revenue (est)

-39%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Omniome News

2022-04-06 - NGS Upstarts Expected to Take On the Champion

The issue, Baker cautions, is that Omniome did not spend much time building the platform. So, although the platform's chemistry may be solid, it...

2022-03-22 - Short-read sequencing by binding

Since acquiring Omniome, PacBio is uniquely positioned as the only company with both highly accurate native long-read and short-read sequencing platforms.

2021-05-04 - Omniome Promotes Richard Shen To President

SAN DIEGO, May 4, 2021 /PRNewswire/ -- Omniome, Inc., developer of an innovative DNA sequencing platform capable of delivering unsurpassed sequencing accuracy, announces the promotion of Richard Shen, PhD to the role of President. Richard brings over 20 years of leadership experience from the Ne ...

2021-05-04 - Omniome Promotes Richard Shen To President

SAN DIEGO, May 4, 2021 /PRNewswire/ -- Omniome, Inc., developer of an innovative DNA sequencing platform capable of delivering unsurpassed sequencing accuracy, announces the promotion of Richard Shen, PhD to the role of President. Richard brings over 20 years of leadership experience from the ...

2021-03-03 - Omniome Appoints Thomas O'Lenic As Chief Commercial Officer

SAN DIEGO, March 3, 2021 /PRNewswire/ -- Omniome, Inc., developer of an innovative DNA sequencing platform capable of delivering unsurpassed sequencing accuracy, announces the appointment of Thomas O'Lenic to the newly created position of Chief Commercial Officer, effective from today's date. ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1M11N/AN/A
#2
$1M11N/AN/A
#3
$1M11N/AN/A
#4
$1M11N/AN/A
#5
$1.1M11N/AN/A

Omniome Funding

DateAmountRoundLead InvestorsReference
2018-07-31$60.0MBDecheng CapitalArticle